In the News

Results from the pivotal FRACTURE trial presented at EuroPCR 2026 showed that Boston Scientific’s investigational SEISMIQ 4CE coronary intravascular lithotripsy catheter met its primary safety and effectiveness endpoints, supporting its potential as a new treatment option for severely calcified coronary lesions during complex PCI procedures.

New data from the AVANT GUARD study suggest that pulsed field ablation (PFA) may be an effective first-line treatment for persistent atrial fibrillation, reducing arrhythmia recurrence compared with antiarrhythmic drug therapy and supporting earlier intervention in selected patients.

Pulsed field ablation is emerging as a promising innovation in the treatment of cardiac arrhythmias. By offering a more targeted approach with the potential for improved safety and efficiency, the technology represents a significant step forward in the evolution of electrophysiology care.

Advances in technology and treatment approaches are ushering in a new era for kidney cancer care. From earlier detection to more targeted therapies, innovation is reshaping how the disease is managed and offering new hope for improved patient outcomes.

Sacral neuromodulation is expanding treatment options for patients with bladder and bowel dysfunction, reinforcing Boston Scientific’s growing urology portfolio in Europe. The therapy highlights the company’s focus on innovative solutions that address unmet clinical needs and improve quality of life.